obinutuzumab (RO5072759)

DRUG2 trials

Sponsors

Hoffmann-La Roche, Zhao Minghui

Conditions

Lupus NephritisNon-Hodgkin's Lymphoma

Phase 2

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

CompletedNCT00576758

Hoffmann-La RocheNon-Hodgkin's Lymphoma

Start: 2008-01-31End: 2013-03-31Updated: 2014-08-19

Phase 3

A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)

Not yet recruitingNCT07767188

Zhao MinghuiLupus Nephritis

Start: 2026-09-10End: 2029-05-08Target: 70Updated: 2026-08-26

Related Papers

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma

Cancer Chemotherapy and Pharmacology2020-03-2818 citations

Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.

2017-02-146 citations

Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)

Blood2014-12-0611 citations

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.

2012-03-20115 citations